10 Result: Merck
What to Expect: Merck, Gilead Sciences, and Bristol-Myers Squibb Earnings on Deck
April 20th, 2025
Notable companies expected to release their financial results on Thursday, April 24, include: Merck & Co., Inc. (NYSE: MRK), known for its innovative portfolio of prescription medicines and vaccines, will report its first-quarter 2025 earnings bef. Read more
Momentum Builds: Bladder Cancer Trial Data Boost Seagen
September 22nd, 2023
Astellas Pharma Inc. and Seagen Inc. (Nasdaq: SGEN) have reported promising results from the Phase 3 EV-302 clinical trial (KEYNOTE-A39) for PADCEV (enfortumab vedotin-ejfv) combined with Merck & Co., Inc.'s (NYSE: MRK) KEYTRUDA (pembrolizumab) versu. Read more
Breaking Biotech Newsflash: Amgen, Gilead Sciences, and Merck
September 10th, 2023
Amgen Inc. (Nasdaq: AMGN) unveiled encouraging data from the CodeBreaK 101 clinical trial, showcasing the effectiveness of LUMAKRAS (sotorasib) plus chemotherapy (carboplatin and pemetrexed) in treating KRAS G12C-mutated advanced non-small cell lung . Read more
Breaking: Tyson Foods Q3 Misses Mark; Ginkgo Bioworks' Merck Deal Shakes Up
August 07th, 2023
Tyson Foods, Inc. (NYSE: TSN) has released its third-quarter fiscal 2023 financial results, reporting adjusted earnings per share (EPS) of $0.15 and revenues totaling $13.14 billion. These figures fell short of market consensus estimates of $0.26 EPS. Read more
Earnings On The Horizon: Merck, Pfizer, AMD, and Caterpillar - A Preview
July 28th, 2023
Multiple companies are set to report their financial results on Tuesday, August 1, including: Merck & Co., Inc. (NYSE: MRK), a pharmaceutical giant, is expected to announce its second-quarter 2023 earnings results prior to the market opening. . Read more
Momentum: Zura Bio, PDS Biotechnology, THOR Industries Making Pre-Market Moves
June 06th, 2023
Zura Bio Limited (Nasdaq: ZURA) has concluded a private placement that generated approximately $80 million in gross proceeds. This funding milestone enables the company to commence a Phase 2 clinical trial for ZB-106, initially targeting sys. Read more
Promising Clinical Trial Updates and Earnings Reports Drive Stock Price Movements: PDS Biotechnology, eFFECTOR Therapeutics, Costco, and Gap
May 26th, 2023
PDS Biotechnology Corporation (Nasdaq: PDSB) and eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) shared promising interim data updates from their respective clinical trials, leading to significant stock price movements in after-hours trading. These develo. Read more
Immutep's Eftilagimod Alpha Shows Promise in Phase II Trial, Lightning eMotors Reports Q1 Loss and $50M Pre-Paid Advance Deal, BioNTech Upgraded to Buy
May 17th, 2023
Immutep Limited (Nasdaq: IMMP) has received positive feedback from the US Food and Drug Administration (FDA) for its late-stage clinical development plans for Eftilagimod Alpha ("efti") in the treatment of 1st line non-small cell lung cancer. In addi. Read more
Lucintel Forecasts Epigenetic Market to grow at a CAGR of 14% from 2019 to 2024
December 08th, 2021
Dallas, TX / CRWE PRESS RELEASE / Dec. 9, 2021 - According to the recent study the Epigenetic Market is projected to grow at a CAGR of 14% from 2019 to 2024. Growth in this market is primarily driven by declining sequencing costs and time, incre. Read more
Lucintel Forecasts Primary Cell Market to Grow at a CAGR of 7%-9%
September 12th, 2021
Dallas, TX / CRWE PRESS RELEASE / Sep. 12, 2021 - According to the recent study the primary cell market is projected to grow at a CAGR of 7%-9% from 2020 to 2025. Growth in this market is primarily driven by increasing cancer research and rapid. Read more
Member Login